May 26, 2022 5:00pm EDT Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
May 16, 2022 5:00pm EDT Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT
May 04, 2022 8:00am EDT Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
Apr 28, 2022 4:30pm EDT Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022
Apr 08, 2022 1:00pm EDT Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors
Mar 14, 2022 8:00am EDT Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
Mar 08, 2022 12:35pm EST Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022
Jan 26, 2022 8:00am EST Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
Nov 12, 2021 7:00am EST Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
